Novogen, Genea testing drugs for genetic diseases
15 November, 2013 by Dylan Bushell-EmblingNovogen (ASX:NRT) has teamed with Genea biocells to test a line of compounds which are effective against cancer stem cells in a range of genetic and degenerative disorders.
Dramatic increase in diabetes unveiled
14 November, 2013A surge in diabetes is occurring in Australia, and across the world, according to the latest IDF Diabetes Atlas.
2013 Research Australia Awards winners announced
14 November, 2013The 2013 Research Australia Awards, held last night at the Park Hyatt in Melbourne, recognised individuals and corporations for areas such as discovery, advocacy, philanthropy and lifetime achievement.
TGA approves Gliolan brain surgery drug
12 November, 2013 by Dylan Bushell-EmblingThe TGA has approved the local availability of Gliolan, a drug for helping brain surgeons remove tumours, through licensee Specialised Therapeutics Australia.
Patrys's SM6 bound for new myeloma trial
11 November, 2013 by Dylan Bushell-EmblingPatrys (ASX:PAB) shares climbed 66% after the company announced a new combination study for one of its anticancer antibodies and the award of a US patent for another.
Government vetoes cap on self-education expenses
07 November, 2013The federal government will not go ahead with a proposed cap on self-education expenses.
Novogen forms ovarian cancer JV
07 November, 2013 by Dylan Bushell-EmblingA joint venture between Novogen (ASX:NRT) and Yale University will focus on developing ovarian cancer drugs, eventually including personalised chemotherapeutic treatments.
Patrys antibody awarded orphan drug status in US
07 November, 2013 by Dylan Bushell-EmblingPatrys (ASX:PAB) now has orphan drug status for antibody PAT-SM6 in multiple myeloma covering the US as well as the EU.
NHMRC recognises researchers' hard work
04 November, 2013The NHMRC has recognised a human molecular geneticist and an IVF researcher with the respective NHMRC Outstanding Contribution Award and the NHMRC Ethics Award.
Prana shares surge on Alzheimer's study results
01 November, 2013 by Dylan Bushell-EmblingShares in Prana Biotechnology (ASX:PBT) climbed 43% after a scientific paper detailed how Alzheimer's drug candidate PBT2 reversed cognitive and memory loss in old mice.
Alchemia gets $8.8m R&D tax rebate for FY13
30 October, 2013 by Dylan Bushell-EmblingAlchemia (ASX:ACL) has received an $8.8m R&D tax incentive windfall, as it benefited from a finding that it can apply for a rebate on some research conducted overseas.
Bridging the gap between health and wellness
30 October, 2013 by Susan WilliamsonFiona Wood reflects on her career choice as a plastic surgeon, combining this with clinical research and the challenges involved in improving clinical outcomes of burns patients.
Celebrating 20 years of medical research policy advocacy
28 October, 2013 by Susan WilliamsonThe Association of Australian Medical Research Institutes celebrates its 20th birthday this week.
Starpharma's docetaxel formula tackles neutropenia
25 October, 2013 by Dylan Bushell-EmblingStarpharma (ASX:SPL) has published a second set of preclinical data suggesting that cancer drugs produced with its dendrimer platform can eliminate bone marrow toxicity neutropenia.
Disturbing infection trends
25 October, 2013Annual survey shows rates of chlamydia, gonorrhoea and syphilis infection are on the increase.
